Économie

Adviser Investments LLC Acquires 2890 Shares of Johnson & Johnson (JNJ)

Adviser Investments LLC Acquires 2890 Shares of Johnson
 & Johnson (JNJ)

Adviser Investments LLC increased its holdings in Johnson & Johnson (NYSE: JNJ) by 11.5% during the third quarter, according to the company’s most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,068 shares of the company’s stock after purchasing an additional 2,890 shares during the quarter. Adviser Investments LLC’s holdings in Johnson & Johnson were worth $ 3,649,000 as part of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of JNJ. Harding Loevner LP bought a new stake in Johnson & Johnson in the 2nd quarter worth $ 106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock at $ 115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock at $ 116,000 after purchasing an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc. bought a new stake in shares of Johnson & Johnson during the second quarter at $ 124,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in Johnson & Johnson’s shares during the second quarter at $ 177,000. Institutional investors own 65.70% of the company’s stock.

Johnson & Johnson ( NYSE JNJ ) opened at $ 145.76 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $ 391,590.00, a PE ratio of 25.31, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80. Johnson & Johnson has a low month of $ 110.76 and a high month of $ 146.42.

Johnson & Johnson (NYSE: JNJ) last issued its earnings on Tuesday, October 17th. The company reported $ 1.90 per share for the quarter, topping the consensus estimate of $ 1.80 by $ 0.10. The business had revenue of $ 19.65 billion during the quarter, compared to analysts’ expectations of $ 19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period, the company earned $ 1.68 per share. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued at $ 0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $ 3.36 annualized dividend and a yield of 2.31%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
JNJ has been the topic of a number of research reports. Vetr reduced shares of Johnson & Johnson from a “hold” rating to a “sell” rating of $ 130.49 target price on the stock. in a research note on Monday, September 18th. Goldman Sachs Group of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their target price for the company from $ 125.00 to $ 130.00 in a research note on Wednesday, September 20th. Citigroup initiated coverage on Johnson & Johnson shares in a research note on Monday, September 25th. They set a “neutral” rating and a $ 140.00 target price on the stock. Zacks Investment Research Johnson & Johnson shares a rating on a Wednesday, September 27th. Finally, UBS Group reissued a “buy” rating and set a $ 148.00. Four research analysts have rated the value of a given rating and have had a hold on the stock. The stock currently has an average rating of “Hold” and an average price target of $ 145.94.
COPYRIGHT VIOLATION WARNING: “Adviser Investments LLC Acquires 2,890 Shares of Johnson & Johnson (JNJ)” was posted by TrueBlueTribune and is owned by TrueBlueTribune. If you are viewing this report on another site, it has been illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2018/01/14/johnson-johnson-jnj-shares-bought-by-adviser-investments-llc.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily – concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies MarketBeat.com’s FREE daily email newsletter .

Post Comment